<DOC>
	<DOCNO>NCT02863055</DOCNO>
	<brief_summary>This multicenter , randomize , 1:1 , double blind phase II trial . Patients unresectable malignant pleural mesothelioma ( MPM ) randomize arm A : nintedanib arm B : placebo</brief_summary>
	<brief_title>Nintedanib Switch Maintenance Treatment Pleural Malignant Mesothelioma</brief_title>
	<detailed_description>This multicenter , prospective , double blind , randomize , two-arm phase II trial aim evaluate nintedanib treatment switch maintenance patient unresectable MPM . After sign informed consent upon confirmation eligibility criterion , patient randomize 1:1 : - Arm A : twice daily nintedanib dose 200 mg progression unacceptable toxicity . - Arm B : match placebo . Response evaluation perform CT scan every 8 week .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Histological diagnosis unresectable Malignant Pleural Mesothelioma ( MPM ) ; Response Stable disease accord modify RECIST criterion [ 48 ] first line platinumpemetrexed chemotherapy 46 cycle ; Last platinum chemotherapy dose administer within 60 day ( i.e . randomization must occur within 60 day last dose last cycle platinumpemetrexed chemotherapy ) ; Age &gt; 18 year ; ECOG performance status ( PS ) 02 ; Life expectancy least 12 week opinion investigator ; Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start first dose prior systemic anticancer therapy include cytotoxic therapy immunecheckpoint inhibitor , MPM , first line platinumbased doublet chemotherapy ; previous extrapleural pneumonectomy ( form previous surgery eg pleurectomy acceptable ) ; previous Vascular Endothelial Growth Factor ( VEGF ) inhibitor ( eg bevacizumab , sorafenib , etc ) ; treatment investigational drug treatment another clinical interventional trial within past 4 week start therapy concomitantly trial ; patient , opinion investigator , reduce performance status 2 ECOG level ( e.g . PS 0 2 PS 1 3 ) begin completion 1st line chemotherapy ; radiotherapy ( exception palliative radiotherapy ) study within 4 week start study drug ; know brain metastasis leptomeningeal disease . Patients suspicious neurological symptom undergo CT scan/MRI brain exclude brain metastasisNo active brain metastasis ( e.g . stable &lt; 4 week ; , adequate previous treatment radiotherapy ; , symptomatic , require treatment anticonvulsant ; dexamethasone therapy allow administer stable dose least one month randomization ) ; patient suspicious neurological symptom undergo CT scan/MRI brain ass brain metastasis ; leptomeningeal metastasis ; significant weight loss ( &gt; 10 % ) within past 6 week prior treatment present trial ; preexist clinically significant ascites and/or clinically significant pleural effusion ; active history bleeding complication would prevent antiangiogenic therapy centrally locate tumor radiographic evidence ( CT MRI ) local invasion major blood vessel ; typical mediastinal pleural involvement mesothelioma remain eligible ; clinically active cancer mesothelioma within 5 year prior start study treatment ; radiographic evidence cavitatory necrotic tumor ; unstoppable use therapeutic anticoagulation ( except low dose heparin and/or heparin flush need maintenance indwell intravenous device ) antiplatelet therapy ( except chronic lowdose therapy acetylsalicylic acid =325mg per day ) ; clinically significant cardiovascular disease ( i.e . hypertension control medical therapy , unstable angina , history myocardial infarction within past 6 month , congestive New York Heart Association ( NYHA ) II , serious cardiac arrhythmia , clinically significant pericardial effusion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MPM</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Phase II</keyword>
	<keyword>Randomized</keyword>
	<keyword>Maintenance</keyword>
</DOC>